Some Dr Pepper Zero soda recalled for having 'full sugar'
The recall affects 19,203 cases of 12 packs and 24 packs of Dr Pepper Zero Sugar 12-ounce cans that were distributed to Florida, Georgia and South Carolina.
The voluntary recall was first initiated on May 23. On June 5, the FDA classified it as a Class II recall.
According to the FDA, a product under a Class II recall may lead to 'temporary or medically reversible adverse health consequences" or a situation "where the probability of serious adverse health consequences is remote.' Sugary drinks can be harmful to anyone, especially if they drink large amounts. People who are at risk of certain conditions such as heart disease, high blood pressure, obesity and type 2 diabetes may want to avoid added sugars like those in sodas, which may contribute to the conditions, according to the Centers for Disease Control and Prevention.
Martinelli's voluntarily recalls apple juice due to potential toxin contamination
A Dr Pepper Zero soda is typically made with aspartame, a sugar substitute, instead of sugar.
Recalled soda cans have a "best by" date of Feb. 16, 2026.
PepsiCo recalls sugar-free Schweppes Ginger Ale for containing 'full sugar'
When reached by ABC News, Dr Pepper's parent company, Keurig Dr Pepper, said recalled cans of soda were produced by a PepsiCo bottling facility that is licensed to make some Keurig Dr Pepper products and that the recalled product has been removed from stores. The beverage company also did not indicate if it received any reports of people impacted by the recall.
Some Dr Pepper Zero soda recalled for having 'full sugar' originally appeared on goodmorningamerica.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
PRP Therapy: What You Need to Know in Passaic County, NJ
Non-surgical treatments are gaining popularity among people seeking relief from discomfort, inflammation, and mobility issues. Among these methods, Platelet-Rich Plasma (PRP) therapy is drawing attention for its ability to support the body's own healing process. It may not be a cure-all, but it has proven to be an option worth exploring when other treatments haven't provided sufficient results. If you're considering PRP therapy in Passaic County, this article offers an overview of how it works, what to expect, and who might benefit from it. PRP therapy involves using a small sample of your blood to isolate and concentrate platelets, which are rich in growth factors. These platelets are then re-injected into the area of concern—whether it's a joint, tendon, or muscle. The goal is to enhance natural healing by stimulating cellular activity in the affected tissues. This therapy does not rely on synthetic drugs or foreign materials. Instead, it utilizes your body's natural components, making it a minimally invasive option for those who prefer to avoid surgery or long-term medication use. Many individuals turn to PRP therapy after traditional treatments haven't produced meaningful improvement. It is commonly considered for: Mild to moderate joint discomfort Tendon strains or partial tears Overuse injuries Muscle pain or inflammation Though the science is still evolving, PRP therapy is being evaluated for a range of musculoskeletal conditions. The most promising use cases are often those that involve soft tissues that struggle to heal on their own. The process begins with a routine blood draw. This blood is then placed in a centrifuge—a machine that spins rapidly to separate the platelet-rich plasma from the other blood components. Once isolated, the PRP is drawn into a syringe and injected into the site that needs healing support. The injection itself takes only a few minutes, and most people are in and out of the clinic within an hour. Some discomfort at the injection site is normal and may include temporary swelling or soreness. Recovery time varies depending on the location and severity of the issue. However, patients are usually able to resume their normal activities within a short period, with guidance from their provider. One of the unique aspects of PRP is its use of your body's own biological material. This reduces the risk of allergic reactions or complications compared to more invasive methods. It also doesn't involve donor tissue or laboratory-grown biologics. Facilities that offer Stem Cell & PRP Therapy in Passaic County NJ often emphasize that their procedures are not based on umbilical cord tissue or outside cell sources. They also follow strict protocols to ensure safety, transparency, and proper patient screening. The equipment used to process PRP is FDA-cleared, but the therapy itself is not formally approved for treating or curing specific medical conditions. PRP is typically considered a supportive or investigational treatment and is offered under physician guidance when appropriate. Practices in Passaic County that offer this therapy are transparent about this and will evaluate whether you're a good candidate before proceeding. Across Passaic County, more people are researching Stem Cell & PRP Therapy in Passaic County NJ as a potential step in managing joint discomfort, tendon injuries, or lingering pain from overuse. While results are not guaranteed, the possibility of using the body's own resources to promote healing can be appealing, especially to those seeking a less invasive approach. Before proceeding, you'll likely meet with a provider to review your health history, current symptoms, and previous treatments. This helps determine if PRP may be an appropriate part of your care plan. If you're considering PRP therapy, here are a few questions to ask during your visit: Am I a good candidate for this procedure? What are the realistic benefits I might expect? How many sessions are typically recommended? What should I do before and after treatment? Are there any side effects I should be aware of? These conversations help set expectations and ensure you're receiving care tailored to your specific situation. Results vary from one person to the next. Some individuals begin to feel improvement within a few weeks, while others may require multiple sessions to notice changes. It's important to keep in mind that PRP is designed to support the body's natural pace of healing—not provide instant relief. Many providers suggest follow-up visits to monitor your response and decide whether additional treatments might be beneficial. Is PRP therapy safe? Yes, since the treatment uses your own blood, the risk of side effects is low. Some mild swelling, bruising, or discomfort at the injection site is common but temporary. Does PRP therapy involve stem cells? No. Standard PRP therapy uses only your own platelet-rich plasma. However, PRP can activate your body's stem cells as part of the natural healing response. Practices offering Stem Cell & PRP Therapy in Passaic County NJ do not use donor-derived or umbilical cord stem cells. Is this covered by insurance? PRP is often considered investigational, so insurance coverage may vary. Be sure to check with your provider ahead of time. Can PRP be used for chronic conditions? It may be recommended in certain chronic cases where inflammation or slow tissue recovery is a concern. However, a full medical evaluation is required to determine suitability. Are results permanent? Results are not permanent. However, some people experience long-term improvement in symptoms, especially when combined with physical therapy or lifestyle adjustments. TIME BUSINESS NEWS
Newsweek
3 hours ago
- Newsweek
Public Health Alert Issued Over Ham Salad: 'Should Be Thrown Away'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Americans have been warned to throw away ham salad products because of potential bacterial contamination. The U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) issued a public health alert on Sunday because of concerns that the products may be contaminated with Listeria monocytogenes. "These products should be thrown away or returned to the place of purchase," the alert said. Newsweek has contacted Newly Weds Foods and Reser's Fine Foods for comment. Why It Matters The FSIS was established to prevent foodborne illnesses and uphold food safety standards, and the agency issues product recalls or public health alerts if it determines that certain food items may pose a health risk. "Listeriosis can cause fever, muscle aches, headache, stiff neck, confusion, loss of balance and convulsions sometimes preceded by diarrhea or other gastrointestinal symptoms," FSIS said in its public health alert. It added, "Persons in the higher-risk categories who experience flu-like symptoms within two months after eating contaminated food should seek medical care and tell the health care provider about eating the contaminated food." What To Know The FSIS issued its public health alert for ham salad products containing breadcrumb products regulated by the Food and Drug Administration (FDA) that have been recalled by Newly Weds Foods over concerns that they may be contaminated with listeria. Listeria monocytogenes can cause serious, and in some cases fatal, infections—particularly in pregnant individuals, newborns, older adults and those with weakened immune systems. The products included in the public health alert are these: 12-ounce printed plastic tubs labeled "RESER'S FINE FOODS Ham Salad" with a sell-by date of September 1, 2025 5-pound clear plastic tubs labeled "Molly's Kitchen Ham Salad" with a sell-by date of August 31, 2025 The issue came to light when Reser's Fine Foods Inc., based in Topeka, Kansas, determined it had used a breadcrumb product regulated by the U.S. Food and Drug Administration (FDA) that was subject to an FDA recall issued over a potential listeria contamination. FSIS warned that some of the affected products may still be in consumers' or retailers' refrigerators or freezers. Consumers who purchased the recalled ham salad are urged not to consume it. Retailers are advised not to sell or serve the products. Instead, the items should be discarded or returned to the place of purchase. At the time of the announcement, there had been no confirmed reports of illness linked to the affected products. However, FSIS advised that anyone concerned about potential illness should contact a health care provider. What Happens Next Consumers with questions about food safety can contact the USDA Meat and Poultry Hotline at 888-MPHotline (888-674-6854) or email MPHotline@
Yahoo
4 hours ago
- Yahoo
After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: After a delay due to 'resource constraints,' the Food and Drug Administration on Monday approved Kalvista Pharmaceuticals' pill Ekterly to treat swelling attacks in people with the rare disorder hereditary angioedema. Ekterly is the first oral drug to treat hereditary angioedema, or HAE, attacks, competing with shots like Firazyr from Takeda and Ruconest from Pharming. Analysts have estimated Ekterly, Kalvista's first marketed drug, could bring in $600 million a year in U.S. sales at its peak. The FDA delayed the decision beyond its June 17 deadline, Kalvista said, because of a 'heavy workload and limited resources.' While Kalvista awaited its decision, the FDA granted approval to another HAE drug, CSL's Andembry, a preventive shot that won't compete directly with Ekterly. Dive Insight: Kalvista set a price of $16,720 per dose, which consists of two 600 milligram tablets of Ekterly, known scientifically as sebetralstat. A company spokesperson stated Kalvista 'priced Ekterly competitively with existing therapies, reflecting the innovation it brings to the HAE community,' noting that it's the first new drug in more than a decade. Under the FDA's approval, people experiencing a HAE attack can take a second dose within three hours if they don't get symptom relief, while people taking Firazyr must wait six, a protocol that could give Ekterly a competitive advantage, Stifel analyst Paul Matteis wrote in a note to clients. Moreover, people using Firazyr and Ruconest must receive training before they can self-inject. The drug won approval based on a trial of 110 people, which found that people who took Ekterly after an attack achieved symptom relief in a median of two hours following a dose within a 12-hour window in which the drug's effectiveness was measured. Fewer than 50% of people who took a placebo in the trial experienced symptom relief within 12 hours. More HAE attacks were resolved in people who took Ekterly within 24 hours, at about 50% compared to 27% in those who took placebo. Kalvista shares rose 24% in early trading, recovering all of the losses following the FDA's delay. Matteis took an optimistic view of the drug, writing that Ekterly's 'injectable-like efficacy has the potential to take a meaningful share, and potentially grow, the on-demand HAE market, which has remained relatively stable.' Recommended Reading Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug Solve the daily Crossword
